QNCX Quince Therapeutics Net earnings per share for the last 12 months

Public company logo of quincetx.com (QNCX)

Quince Therapeutics (QNCX) is developing a unique drug delivery method via erythrocytes, while management focuses on M&A transactions and investor protection. The fundamental EPS TTM metric helps assess the issuer's financial stability, with -124.48 representing the latest level. To develop drugs for bone pathologies, Quince Therapeutics is implementing AI algorithms and partially automating laboratory synthesis.

QNCX (Quince) Net earnings per share (EPS TTM) history from 04/28/2023 to 10/12/2026

Analytical breakdowns and data insights for company Quince Therapeutics (QNCX)

- stock price and consensus target price:
Fundamental company valuation:Quince Therapeutics (QNCX)
Mass-produced product of Quince

Conservative capital demands maximum transparency in profit distribution among shareholders. This indicator measures the portion of net income attributable to a single common share over a rolling year, excluding the impact of one-time factors. For Quince Therapeutics (QNCX), which is developing innovative treatments for rare pathologies, this metric reflects the efficiency of capitalizing scientific achievements. Analyzing the 12-month rolling earnings per share history allows for a comparison of actual returns against market expectations.

Competitors of Quince Therapeutics

Ascendis - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Madrigal Pharma|CORT (Corcept Therapeutics Incorporated) - Net earnings per share for the last 12 months|RYTM: Earnings per share for the last four quarters|AKRO (Akero Corp) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) Metsera Inc|Net earnings per share (EPS TTM) MLTX|Earnings per share for the last twelve months CRNX (Crinetics Pharmaceuticals, Inc.)|Earnings per share for the last twelve months newamsterdampharma.com NAMS|Soleno Therapeutics Corp (SLNO) - Net earnings per one share for the last twelve months|FOLD - Earnings per share for the last twelve months|ETNB: Earnings per share for the last twelve months|AGIO: Net earnings per share (EPS TTM)|GPCR - Net earnings per share for the last four quarters|Earnings per share for the last twelve months MiMedx Corp|Rezolute Bio (RZLT) - Net earnings per share for the last four quarters|Earnings per share for the last twelve months lexpharma.com (LXRX)|Net earnings per share for the last 12 months MBX Biosciences Inc MBX|Earnings per share for the last twelve months Altimmune ALT|Net earnings per share (EPS TTM) Aardvark Therapeutics AARD|Sagimet Biosciences, Inc. - Net earnings per share (EPS TTM)|Net earnings per share for the last four quarters BioAge Labs, Inc BIOA|Biomea Fusion Inc (BMEA) - Earnings per share for the last twelve months|Fractyl Health, Inc. (GUTS) - Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months VTVT|Agape ATP Corporation - Earnings per one share for the last 12 months|Net earnings per share (EPS TTM) PLUR|SYBX - Net earnings per one share for the last twelve months|Net earnings per share (EPS TTM) LPCN (lipocine.com)|Net earnings per share (EPS TTM) Matinas BioPharma MTNB|SPRB: Net earnings per share for the last 12 months|Net earnings per one share for the last twelve months Galecto Corp|CTCX (Carmell Corp) - Net earnings per share for the last 12 months|Lumos Pharma Corp - Earnings per share for the trailing year|Net earnings per share for the last 12 months ONVO|Net earnings per one share for the last twelve months Radius Recycling, Inc. RDUS